Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
38.04 19.61 19.93 12.75

+8 more quarters

P/S ratio
3.18 2.72 2.61 2.04
P/FCF ratio
12.56 11.24 12.77 9.08
P/Operating CF
71.09 41.81 50.37 16.14
P/B ratio
1.69 1.45 1.41 1.13
Price to Tangible BV
0.00 8.68 9.97 8.61
EV/Sales
3.78 2.92 2.86 2.27
EV/EBITDA
14.71 9.57 9.62 7.23
EV/Operating CF
13.17 11.19 12.82 9.32
EV/FCF
14.93 12.07 13.99 10.11
Quick Ratio
0.81 1.88 1.54 1.62
Current Ratio
1.87 3.06 2.68 2.72
Net Debt/EBITDA
10.18 2.83 5.84 2.72
Debt/Assets
22.72% 21.33% 21.35% 21.52%
Debt/Equity
0.39 0.34 0.34 0.35
Asset Turnover
0.33 0.35 0.34 0.35
Operating CF/Net income
4.60 2.02 (10.47) 2.73
Capex/Depreciation
(0.40) (0.16) (0.19) (0.20)
Research and Development Expense of Revenue
19.36% 21.75% 22.35% 17.21%
Selling, General and Administrative Expense of Revenue
25.94% 24.51% 29.94% 23.47%
Intangible Assets out of Total Assets
0.64 0.53 0.53 0.54
Share Based Compensation of Revenue
2.83% 3.39% 2.61% 2.97%
Graham Net Nets
(0.19) (0.06) (0.09) (0.10)
Graham Number
127.71 163.27 157.35 175.25
Earnings Yield
2.63% 5.10% 5.02% 7.85%
Free Cash Flow Yield
7.96% 8.90% 7.83% 11.02%
Revenue per Share
18.52 16.83 15.56 17.29
Operating CF per Share
3.04 4.39 3.49 8.68
Capex per Share
(1.19) (0.35) (0.41) (0.35)
Free Cash Flow per Share
1.85 4.04 3.08 8.33
Cash per Share
8.70 29.09 26.05 27.02
Shareholders Equity per Share
127.61 126.71 124.62 124.20
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
127.61 126.71 124.62 124.20
Free Cash Flow
273.00 594.30 451.70 1,221.00
Working Capital
3,388.60 6,191.50 5,624.70 5,646.60
Capital Expenditures
(175.90) (51.20) (60.20) (51.50)
Net Current Asset Value
(5,932.90) (1,641.00) (2,208.60) (2,063.40)
EV/EBIT
30.63 15.42 15.17 10.37
Capex to Sales
0.06 0.02 0.03 0.02
Price to Operating Income
25.78 14.36 13.85 9.31
Other line items
Average Receivables
1,754.90 1,682.85 1,373.60 1,455.15
Average Payables
406.15 375.00 428.10 417.90
Average Inventory
2,329.30 2,111.45 2,314.30 2,339.30
Average Assets
30,208.40 28,758.10 28,744.40 28,760.35
Average Common Equity
18,241.00 17,815.20 17,486.40 17,283.20

Fold the line items

Columns are period end dates